Diabetes reversed in mice, FDA approves human trial
The FDA approved the start of a clinical trial to evaluate the safety and feasibility of the treatment. The trial is expected to begin sometime this spring and
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.
The double-blind, placebo-controlled clinical study is designed to assess the safety, tolerability and pharmacokinetics of a subcutaneous injection of PulmoLar. PulmoLar is PRP’s proprietary sustained-release injectable formulation of